ESMO 2022 | PUCCINI: early metabolic response predicts survival in patients with mBC receiving CDK4/6 inhibitors

Elisa Agostinetto, MD, Institut Jules Bordet, Brussels, Belgium, presents preliminary data from the PUCCINI study, which aimed to predict survival in patients with metastatic breast cancer receiving CDK4/6 inhibitors through early metabolic response by FDG-PET. In this study, it was found that early metabolic response by FDG-PET scan in patients with metastatic breast cancer receiving CDK4/6 inhibitors and endocrine therapy is associated with longer progression-free survival. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.